20240050442. TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER simplified abstract (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
Contents
- 1 TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Original Abstract Submitted
TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER
Organization Name
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventor(s)
TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240050442 titled 'TRIMEPRAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING A NEUROPSYCHIATRIC DISORDER
Simplified Explanation
The present invention is about trimeprazine derivatives that can be used to treat neuropsychiatric disorders such as intellectual disability (ID), fragile X syndrome (FXS), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD). The invention also includes pharmaceutical compositions containing these derivatives.
- Trimeprazine derivatives of formula (i) are used for treating neuropsychiatric disorders.
- The specific disorders that can be treated include intellectual disability (ID), fragile X syndrome (FXS), autism spectrum disorders (ASD), and attention deficit hyperactivity disorder (ADHD).
- The invention also includes pharmaceutical compositions that contain these trimeprazine derivatives.
Potential Applications
- Treatment of intellectual disability (ID)
- Treatment of fragile X syndrome (FXS)
- Treatment of autism spectrum disorders (ASD)
- Treatment of attention deficit hyperactivity disorder (ADHD)
Problems Solved
- Lack of effective treatments for intellectual disability (ID)
- Limited treatment options for fragile X syndrome (FXS)
- Limited treatment options for autism spectrum disorders (ASD)
- Limited treatment options for attention deficit hyperactivity disorder (ADHD)
Benefits
- Provides a potential treatment option for intellectual disability (ID)
- Offers a new approach for treating fragile X syndrome (FXS)
- Provides a potential treatment option for autism spectrum disorders (ASD)
- Offers a new approach for treating attention deficit hyperactivity disorder (ADHD)
Original Abstract Submitted
the present invention relates to trimeprazine derivatives of formula (i) for use for treating a neuropsychiatric disorder chosen among an intellectual disability (id), preferably fragile x syndrome (fxs), autism spectrum disorders (asd), and attention deficit hyperactivity disorder (adid). the invention also relates to pharmaceutical compositions for use comprising such derivatives.
